Chronic Obstructive Pulmonary Disease Treatment Market (By Drug Class: Bronchodilators, Combination, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, Corticosteroids, Others; By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2018 - 2026

Introduction

Global chronic obstructive pulmonary disease treatment market income is anticipated to value around USD 24.3 billion by the end of 2026. The market is anticipated to develop with a CAGR of 4.9% between the years 2018 to 2026.

Market Dynamics

The market is driven by Increase in the numeral of COPD cases, increase in FDA approval, and continuous launch of a few products in the U.S. In addition, increment in the geriatric populace and rise in use on pharmaceuticals in rising nations are alternate components adding to the development of the market. Nonetheless, patent expiry of marked products and accessibility of conventional counterparts and elective treatment alternatives are foreseen to control the worldwide market.

High occurrence of COPD, promising medications in pipeline, development of the pharmaceutical business in developing markets, for example, Asia Pacific, and launch of products, for example, inhalers are anticipated to increase the worldwide market from the year 2018 to 2026.

Market Insights

Increase in commonness of COPD, high environmental contamination, increment in the geriatric populace, and development of the pharmaceutical business are foreseen to fuel the development of the chronic obstructive pulmonary disease (COPD) treatment market in Asia Pacific. An article published in the International Journal of Pulmonary and Respiratory Sciences expressed that COPD is the third driving reason for death in India.

On the basis of drug class, the worldwide chronic obstructive pulmonary disease treatment market has been sectioned into bronchodilators, combination, phosphodiesterase type 4 inhibitors, corticosteroids, mucokinetics, and others. The combination segment has been segmented into long acting beta agonist & inhaled corticosteroids (LABA-ICS), triple therapy, long acting muscarinic antagonist & inhaled corticosteroids (LAMA-ICS), and others. The bronchodilators segment has been bifurcated into short acting beta agonist (SABA), long acting beta agonist (LABA), and long acting muscarinic rival (LAMA). The combination segment is anticipated to represent major share of the market by 2026 because of increment in number of doctors recommending combination treatment and increase in the number of medications accessible for COPD treatment. The bronchodilators segment is foreseen to develop at a steady pace attributable to increment in the appropriation of long acting muscarinic rival (LAMA) drugs.

Market Segmentation

Market By Drug Class

• Bronchodilators
• Combination
• Phosphodiesterase Type 4 Inhibitors
• Mucokinetics
• Corticosteroids
• Others

Market By Distribution Channel

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Market By Geography

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • Rest of MEA

Regional Insights

Based on the region, the worldwide chronic obstructive pulmonary disease (COPD) treatment market has been classified into Europe, North America, Asia Pacific, Middle East and Africa, and Latin America. North America represented the biggest revenue share of the worldwide market in 2018. Presence of built up pharmaceutical organizations, increment in adoption of new drugs propelled in the market, and concentrate on dispatch of new products through R&D are foreseen to drive the market in the area amid the estimate time frame.

The chronic obstructive pulmonary disease (COPD) treatment industry in Europe is driven by increment in R&D spending and introduction of new products. In November 2018, GlaxoSmithKline plc and Innoviva, Inc. gotten approval from the European Commission for extended use for once-daily TrelegyEllipta, first single inhaler triple treatment demonstrated for COPD patients who were not enough treated with dual bronchodilation.

Market Participants

Main enterprises working in the global chronic obstructive pulmonary disease treatment market are Orion Corporation, AstraZeneca, Mylan N.V., BoehringerIngelheim Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc. and CHIESI Farmaceutici S.p.A.